sacituzumab govitecan
sacituzumab govitecan: developed by 1 company · 25 clinical trials tracked.
sacituzumab govitecan evidence translation
What we can confirm
25 tracked trials
What it means
What to watch
Prepared research question
How could sacituzumab govitecan → IMMU affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 6 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| IMMUNOMEDICS INC (IMMU) metastatic triple-negative breast cancer (mTNBC) | Phase 3 |
Clinical Trials (25)showing 10 most recent
NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Primary endpoint: Cohort I: 3-year event-free survival (EFS)
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Primary endpoint: Disease Control
A Single-Arm, Phase II Prospective Study Of Lucanoximab Combined With Tagolimab As Neoadjuvant Therapy For Resectable Head And Neck Squamous Cell Carcinoma
Primary endpoint: Major Pathological Response Rate (MPR)
Phase Ib Randomized Open-label Trial of Sacituzumab Govitecan Plus Nivolumab or Sacituzumab Govitecan Plus Nivolumab and Relatlimab as Second-line Therapy for Patients With Metastatic Triple Negative Breast Cancer
Primary endpoint: Incidence and severity of dose limiting toxicities in patients treated with sacituzumab govitecan combinations
Phase I/II Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Primary endpoint: Safety and Adverse Events (AEs)
A Phase II Study of Sacituzumab Govitecan in Combination With Cetuximab in Patients With Recurrent Metastatic HNSCC That Has Progressed After First-Line Therapy
Primary endpoint: Objective Response Rate
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Primary endpoint: Overall Survival (OS)
NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan Versus Sacituzumab Govitecan+Pembrolizumab in Low-risk, Triple-negative Early Breast Cancer (ADAPT-TN-III)
Primary endpoint: pathological complete remission (pCR)
SERIES: SEquencing Sacituzumab Govitecan AfteR T-DXd In ER+/HER2 LOW/ULTRA LOW MetaStatic Breast Cancer
Primary endpoint: Overall response rate (ORR)
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Bladder Preservation in Patients With MIBC (RAD-SG).
Primary endpoint: Rate of acute-dose limiting toxicities
Frequently asked questions
Who is developing sacituzumab govitecan?
sacituzumab govitecan is being developed by IMMUNOMEDICS INC.
How many clinical trials involve sacituzumab govitecan?
BioSniper tracks 25 clinical trials involving sacituzumab govitecan.